Karman Space & Defense at Jefferies: growth, capacity and cash

Karman Space & Defense reiterated approximately 25% organic growth and EBITDA margins above 30%, citing sustained missile, munitions, space-launch and maritime-defense demand. The company is adding a 200,000-square-foot Salt Lake City facility that could expand launch-system capacity 4x and solid-rocket-motor capacity 2x, while targeting roughly 80% normalized cash conversion as it improves working capital. Karman also expanded into Europe through Walker Precision Engineering, adding exposure to 25 European missile programs, though its shares remain down about 66% over six months near a 52-week low.

Analysis

KRMN's valuation dislocation is unlikely to close simply on another earnings beat: the market is discounting execution risk from simultaneously commissioning capacity, transferring qualified processes, and integrating acquired operations. The near-term gating item is cash, not EBITDA. A credible 2027 framework showing conversion toward the stated target, alongside stable contract-asset intensity, would shift the investor debate from "serial acquirer with working-capital drag" to a scarce pure-play defense supplier and could drive multiple expansion over 6-12 months.

The capacity build creates a non-linear upside case in 2027-28 if missile-prime production schedules translate into releases, because incremental volumes can absorb fixed manufacturing costs without requiring comparable new commercial infrastructure. Conversely, qualification delays or lower initial utilization would depress free cash flow before they visibly affect reported EBITDA. KRMN's willingness to use price to win second-source positions also means revenue acceleration should not automatically be read as margin-accretive; watch segment-level gross margin and bid discipline rather than consolidated EBITDA alone.

The underappreciated strategic asset is European manufacturing localization. If European procurement increasingly favors local content, KRMN can become a conduit for U.S. primes including LMT and LHX to preserve program access without recreating specialized supply chains locally. That is a multi-year option rather than a near-term earnings catalyst, and its value depends on winning funded production work rather than cross-selling rhetoric. The immediate macro risk is higher rates: a long-duration, cash-flow-light growth industrial can remain de-rated despite defense demand if real yields rise.

Key Decisions for Investors

• Initiate a staged long KRMN over the next 1-3 months only after confirming next-quarter contract assets grow no faster than revenue and management provides a measurable 2027 free-cash-flow bridge. Target 12-18 month upside from cash-conversion rerating; risk is a capacity/qualification slip that pushes conversion below the stated 80% aspiration.
• Use a defined-risk structure rather than outright size ahead of the next earnings release: buy 6-9 month KRMN call spreads, financed only opportunistically with far-out-of-the-money puts. The catalyst is cash-flow guidance and evidence of facility ramp; exit if EBITDA margins fall materially below the stated steady-state range or working-capital intensity reverses.
• Pair long KRMN / short a broad aerospace-and-defense proxy such as ITA only after KRMN establishes operational ramp milestones. This isolates the idiosyncratic cash-conversion and localization rerating from broad defense-budget or rate sensitivity; do not initiate if no liquid borrow/options market is available.
• Maintain LMT and LHX as read-through alerts, not directional trades: monitor European missile contract awards and local-content requirements. Announced localized production or incremental interceptor procurement would validate a 2027-28 supplier-volume tailwind for KRMN, while delayed procurement appropriations would falsify the near-term demand conversion thesis.